1. Structure of a glomulin-RBX1-CUL1 complex: inhibition of a RING E3 ligase through masking of its E2-binding surface.
- Author
-
Duda DM, Olszewski JL, Tron AE, Hammel M, Lambert LJ, Waddell MB, Mittag T, DeCaprio JA, and Schulman BA
- Subjects
- Adaptor Proteins, Signal Transducing metabolism, Anaphase-Promoting Complex-Cyclosome, Binding Sites physiology, Carrier Proteins metabolism, Crystallography, X-Ray, Cullin Proteins metabolism, Glomus Tumor metabolism, Humans, Models, Chemical, Mutagenesis physiology, Paraganglioma, Extra-Adrenal metabolism, Protein Binding physiology, Protein Folding, Protein Structure, Tertiary physiology, Structure-Activity Relationship, Substrate Specificity physiology, Ubiquitin-Conjugating Enzymes, Ubiquitin-Protein Ligase Complexes chemistry, Ubiquitin-Protein Ligase Complexes metabolism, Ubiquitin-Protein Ligases metabolism, Adaptor Proteins, Signal Transducing chemistry, Carrier Proteins chemistry, Cullin Proteins chemistry, Ubiquitin-Protein Ligases antagonists & inhibitors, Ubiquitin-Protein Ligases chemistry, Ubiquitination physiology
- Abstract
The approximately 300 human cullin-RING ligases (CRLs) are multisubunit E3s in which a RING protein, either RBX1 or RBX2, recruits an E2 to catalyze ubiquitination. RBX1-containing CRLs also can bind Glomulin (GLMN), which binds RBX1's RING domain, regulates the RBX1-CUL1-containing SCF(FBW7) complex, and is disrupted in the disease Glomuvenous Malformation. Here we report the crystal structure of a complex between GLMN, RBX1, and a fragment of CUL1. Structural and biochemical analyses reveal that GLMN adopts a HEAT-like repeat fold that tightly binds the E2-interacting surface of RBX1, inhibiting CRL-mediated chain formation by the E2 CDC34. The structure explains the basis for GLMN's selectivity toward RBX1 over RBX2, and how disease-associated mutations disrupt GLMN-RBX1 interactions. Our study reveals a mechanism for RING E3 ligase regulation, whereby an inhibitor blocks E2 access, and raises the possibility that other E3s are likewise controlled by cellular proteins that mask E2-binding surfaces to mediate inhibition., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF